secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001104659-25-058893
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics elects three Class II directors, ratifies PwC
------------------------------------------------------------------------

- Class II directors elected: Behbahani (14.5M for, 20.0M withheld), Menzel (33.5M for, 0.96M withheld), Kulkarni (14.2M for, 20.3M withheld); 8.5M broker non-votes each.
- Ratification of PwC as auditor for FY2025 passed: 42.48M for, 0.45M against, 59k abstain.
- Annual meeting held June 12, 2025 with 42.99M shares present out of 56.68M outstanding, establishing quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465925058893/0001104659-25-058893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465925058893/tm2517877d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-058893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer